Study: Inosit, Betain and Boswellia for breast health

Veröffentlicht:

Aktualisiert:

Von:

Dieser Artikel ist Teil der Sonderausgabe Frauengesundheit 2017. Lesen Sie die vollständige Ausgabe oder lade es herunter hier. Bezug Pasta V, Dinicola S, Giuliani A, et al. Eine randomisierte Pilotstudie zu Inositol in Verbindung mit Betain und Boswellia bei der Behandlung von Mastalgie und gutartigen Knoten in der Brust bei prämenopausalen Frauen. Brustkrebs (Auckl). 2016;10:37-43. Entwurf Eine 6-monatige doppelblinde, placebokontrollierte, randomisierte klinische Studie wurde durchgeführt, um die Sicherheit und Wirksamkeit von Boswelliasäure, Betain und Myo-Inositol bei der Behandlung von Mastalgie und gutartigen Knoten in der Brust zu bewerten. Teilnehmer Insgesamt 76 prämenopausale Frauen im Alter von 22 bis 51 Jahren …
This article is part of the special edition of women's health 2017. Read the full edition or download it here. Relation Pasta V, Dinicola S, Giuliani a, et al. A randomized pilot study on inositol in connection with Betain and Boswellia in the treatment of mastalgia and benign nodes in the chest in pre -menopausal women. Breast cancer (Auckl). 2016; 10: 37-43. Draft a 6-month double-blind, placebo-controlled, randomized clinical study was carried out to evaluate the security and effectiveness of boswellias, betain and myo-inositol in the treatment of mastalgia and benign nodes in the chest. Participants a total of 76 premenopausal women between the ages of 22 and 51 ... (Symbolbild/natur.wiki)

This article is part of the special edition of women's health in 2017. Read the full edition or download it here.

reference

pasta V, Dinicola S, Giuliani a, et al. A randomized pilot study on inositol in connection with Betain and Boswellia in the treatment of mastalgia and benign nodes in the chest in pre -menopausal women. breast cancer (Auckl) . 2016; 10: 37-43.

draft

A 6-month double-blind, placebo-controlled, randomized clinical study was carried out to evaluate the security and effectiveness of boswellias, betaine and myo-inositol in the treatment of mastalgia and benign nodes in the chest.

participant

A total of 76 pre -menopausal women between the ages of 22 and 51 with mild to heavy mast algia for more than 6 months were included in the study. Those who had received treatment against mast algia within 4 months of the study, hormonal contraceptives or underwent other endocrine treatments were excluded. Further exclusion criteria were the presence of breast nodes diagnosed as breast cancer, atypical lobular hyperplasia, sclerosing adenosis, anemia or metabolic disorders.

After the randomization, the type of mastalgia (cyclical, non -cyclical or extramammer) and the degree of breast density (almost completely fat, scattered fibroglandular density, heterogeneous or extremely densely) was determined.

Intervention

The participants in the control group received oral capsules, each contained vitamin B6 (2.1 mg), riboflavin (2.1 mg), folic acid (300 µg), vitamin B12 (3.75 µg) and N-acetylcysteine ​​(100 mg). The test group received a dietary supplement called Eumastós, which contained the same combination with the addition of myo-inositol (200 mg). Boswellia Serrata (50 mg) and Betain (175 mg). All participants were instructed to take 2 capsules twice a day.

target parameter

Primary endpoint was the improvement of mast algia, measured by patient questionnaires that were preserved for 3 and month 6 in randomization. Secondary endpoints included reducing the benign breast node size (more than 20 % of the original diameter) and the mammographically measured total density of the breast. The relief of the following frequent accompanying symptoms were mentioned as additional measures: anxiety, menstrual pain, nipple discharge, headache and nausea.

important knowledge

of the 76 enrolled women completed the study in 62. Four participants were lost to tracking; However, 2 of the 4 reported an improvement during a telephone interview.

among those who classified their pain as cyclical, 56.2 % of the test group experienced an improvement compared to 16.6 % of the control group. In addition, 36.8 % of the former reported an almost complete disappearance of the pain after completing the study. Of those with non -cyclical pain, 61.5 % of the test group reported on relief compared to 16.6 % of the control group. The relief of both cyclical and non -cyclical breast pain achieved statistical significance (cyclical, p = 0.025; non -cyclical, p = 0.29).

Supplement with shared doses of Myo-Inositol (800 mg), Boswellia Serrata (200 mg) and Betain (700 mg) can be valuable new therapy in the treatment of patients with mast alga, benign breast diseases and/or high breast density.

reductions of the nodula size occurred in the test group with a rate of 40.7 %, while only 16 % of the control group showed an improvement ( p = 0.07). An deterioration (dimension gain) was not observed in any group.

twenty -five of 32 (78 %) women in the test group and 22 out of 30 (73 %) women in the control group had extremely dense breast tissue at the beginning of the course. No changes were reported in the control group at the end of the study; 15, however, had a significant reduction in the density ( p = 0.001) in the test group.

The relief of fear occurred independently of the treatment; However, significantly higher rates of improving the menstrual pain among those who earned Boswellia, Betain and Myo-Inositol were found. The improvement of all other symptoms was not significant in any group.

practice implications

These results indicate that moderate doses of several frequently used nutritional supplements can improve the symptoms that affect many of our pre -menopausal patients.

Despite the fact that chest pain (mastalgia) is usually benign nature and result from cyclical hormone fluctuations or benign breast diseases, it is a symptom that often causes a considerable concern until a further examination was carried out. impaired. 2 Therefore, a low -risk intervention is required to relieve this symptom.

Several studies indicate that a high breast density is a genetic but possibly modifiable risk factor for breast cancer. 3.4 Anti -ecliped drugs such as tamoxifen were successful in reducing the density and relief of mast alg; However, accompanying side effects often outweigh the advantages.

The design of the present study shows that not all ingredients (B vitamins and n -acetylcystein) are essential for the achievement of documented advantages. However, previous literature that shows the individual therapeutic effects of Boswellia, Betain and Myo-Inositol helps us to understand how they can be effective in the treatment of mastalgia and other breast-related diseases. Based on its ability to modulate inflammation, in particular by inhibiting the 5-lipoxygenase, Boswellia has proven to be effective in the treatment of different chronic inflammatory diseases. 6 It has also been shown that Betain, which is generally known for its use in the treatment of hypochlor hydras, improves breast health. Several earlier work has reported on an opposite connection between the beta intake and the risk of breast cancer. 7.8 It was found that myo-inositol, a chemical mediator of insulin, improves hormonal and metabolic parameters, especially in women with polycystic ovarian syndrome (PCOS). Notes that myo-inositol can modulate inflammatory and oxidative processes. In view of the popularity of myo-inositol for the treatment of PCOS, this raises the question of whether the creators of Eumastós have taken into account the possible correlation between PCOS and the prevalence of benign breast diseases (BBD) when formulating their product. There was no mention of such an association of you or the authors of the paper; However, several, but not all studies indicate a relationship.

In 2000, d’Amelio et al. About BBD in about 7 % of women with normal -looking ovaries, 57 % of women with ovarian cysts and 92 % of women with diagnosed PCOS. 12 in a similar study (n = 93), which was carried out in 2009, gumus et al. Also stated that BBD appears significantly more frequently in women with PCOS (40 %) than in women without (12.5 %). 13 These studies show a clear correlation, but a clinical study from 2005 (n = 240) by Soran et al suggests something different. In this study, the rates of fibrocystic breast disease, node thickening, fibroadenoma, calcification, pain, redness, discharge and hyperplasia were present both in the test and control group.

In 2012, Ozkaya et al. A study to determine whether hyperandrogenemia (HA) acts as a protective factor against fibrocystic breast diseases. The participants were categorized according to PCOS phenotype (Group 1: PCO anovulation; Group 2: HA-Anovulation; Group 3: HA-PCO; Group 4: HA-PCO anovulation) and then evaluated using various metabolic and hormonal parameters. People in group 3 had the lowest rates of fibrocystic breast disease, while those in group 1 had the highest rates.

The authors of this present study (Pasta et al.) carried out a very similar clinical study just one month after the publication of this first (pilot) study. In the second study, 64 women were recruited with fibradenomes aged 30 or disciples and randomized in 2 groups; A group received the same placebo as in the pilot study and the second group received the same company -owned formula (Eumastós). After 6 months it was found that the reduction of the middle fibroadenom volume in the test group was more common (38.88 % vs. 17.85 %) and significant (17.86 % vs. 5.96 %).

These results continue to support the hypothesis that Myo-Inositol, Boswellia and Betain are an advantage for breast health when combined.

according to the results of both clinical studies by Pasta et al. Should a supplementation with shared doses of myo-inositol (800 mg), boswellia Serrata (200 mg) and Betain (700 mg) can be a valuable new therapy in the treatment of patients with mast alga, BBD and/or high breast density. In addition, this combination can be particularly effective in the treatment of patients with PCOS and simultaneous BBD.

  1. Santen R, Mansel R. Current concepts: benign breast diseases. n Engl. J med 2005; 353: 275-285.
  2. j. Scurr, W. Hedger, P. Morris et al. The prevalence, severity and effects of chest pain in the general population. breast j . 2014; 20 (5): 508-513.
  3. Ursin G, Qureshi Sa. Mammographical density - a useful biomarker for the risk of breast cancer in epidemiological studies. norsk epidemiologi . 2009; 19: 59-68.
  4. Boyd NF, Martin LJ, Yaffe MJ, et al. Mammographical density and breast cancer risk: current understanding and future prospects. breast cancer resist . 2011; 13: 223.
  5. Pasta V, Dinicola S, Giuliani a, et al. A randomized study with Boswellia in connection with betaine and myo-inositol in the treatment of breast fibradenomes. EUR. Rev. med. Pharmacol. Sci . 2016; 20 (9): 1860-5.
  6. Ammon HP. Boswelliac acids in chronic inflammatory diseases. Planta Med . 2006; 72 (12): 1100-1116.
  7. Zhang CX, Pan MX, Wang L, et al. Conversely, the recording of choline and betain is associated with the risk of breast cancer: a two-stage case control study in China. cancer science . 2013; 104 (2): 250-258.
  8. du yf, lin fy, long wq, et al. Serumbetain, but not choline, is conversely associated with the risk of breast cancer: a case control study in China [published online AHead of print, February 20, 2016]. EUR J Nutr .
  9. unfer V, Nestler Je, Kamenov Za, et al. Effects of inositol (s) in women with PCOS: a systematic review of randomized controlled studies. intj Endocrinol . 2016; 2016: 1849162.
  10. Liao J., Seril DN, Yang al, et al. Inhibition of adenocarcinoma development associated with chronic ulcerative colitis in mice due to inosite compounds. carcinogenesis . 2007; 28: 446-454.
  11. Dona G., Sabbadin C., Fiore C., et al. The administration of inositol reduces oxidative stress in erythrocytes of patients with polycystic ovarian syndrome. EUR J ENDOCRINOL . 2012; 166: 703-710.
  12. d’amelio R, Farris M, Grande S, et al. Incidence of a fibrocystic disease of the breast in women with polycystic ovar. Clinical-instrumental study. Minerva Ginecol . 2000; 52 (9): 321-325.
  13. Gumus I, Koktener A, Dogan d, et al. Polycystic ovarian syndrome and fibrocystic breast disease: Is there a connection? ore gynecologist fruit . 2009; 280 (2): 249-253.
  14. Soran A, Talbott E, Zborowski J, et al. The prevalence of benign breast diseases in women with polycystic ovarian syndrome: a review of a 12-year follow-up. int. J. Clin. Pract . 2005; 59 (7): 795-797.
  15. Ozkaya E., Cakir E., Cinar M. et al. Protects hyperandrogenemia from fibrocystic breast disease in PCOS? gynecol endocrinol . 2012; 28 (6): 468-471.